The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 22, 2015

Filed:

Aug. 19, 2011
Applicants:

Victoria Mary Perreau, Parkville, AU;

Judith Field, Parkville, AU;

Michele D Binder, Parkville, AU;

Trevor Kilpatrick, Parkville, AU;

Inventors:

Victoria Mary Perreau, Parkville, AU;

Judith Field, Parkville, AU;

Michele D Binder, Parkville, AU;

Trevor Kilpatrick, Parkville, AU;

Assignee:

HOWARD FLOREY INSTITUTE, Parkville, Victoria, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); C12Q 1/68 (2006.01); G01N 33/68 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); A61K 39/3955 (2013.01); C07K 16/2863 (2013.01); G01N 33/6896 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/91215 (2013.01); G01N 2800/285 (2013.01); G01N 2800/56 (2013.01);
Abstract

Methods, compositions and kits based on TAM receptors, or TAM receptor ligands or agonists are for detection of neuropathological diseases or determination of their progression. The neural diseases include multiple sclerosis or other inflammatory neural disorders that are characterized by demyelination, oligodendrocyte cytotoxicity and microglial activation. These methods include screening cells of a subject where identification of an elevation of expression of a TAM receptor or a change in expression of a TAM receptor ligand indicates the presence of the disease presence or progression. In addition, subjects with such neuropathological diseases can be treated by administering TAM receptor ligands (such as GAS 6 or Protein S) or by administering agonists such as antibodies specific for the TAM receptors; Axl, Mer or Tyro3.


Find Patent Forward Citations

Loading…